Adenoviral-vector mediated transfer of HBV-targeted ribonuclease can inhibit HBV replication in vivo

Biochemical and Biophysical Research Communications

Volumn 371, Issue 3, 2008, Pages 541-545

  Zhao, Ya ^a   Li, Yinghui ^a   Liu, Jun ^a   Liu, Zhongxiang ^a   Huang, Yuxiao ^a   Lei, Junchuan ^a   Li, Shumei ^a   Xue, Caifang ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Adenovirus; Gene therapy; HBV; Targeted ribonuclease

Indexed keywords

ADENOVIRUS VECTOR; GENOMIC DNA; HEPATITIS B SURFACE ANTIGEN; RIBONUCLEASE; VIRUS DNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG BLOOD LEVEL; EMBRYO; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LIVER; LIVER CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSGENIC MOUSE; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; ANTIBODIES, VIRAL; DNA, VIRAL; EOSINOPHIL-DERIVED NEUROTOXIN; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEPATITIS B VIRUS; HUMANS; MICE; MICE, TRANSGENIC; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; VIRAL CORE PROTEINS; VIRUS REPLICATION;

ADENOVIRIDAE; HEPATITIS B VIRUS; MUS; MUS MUSCULUS;

EID: 43549126625     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.04.121     Document Type: Article

References (21)

1. Alter M.J. Epidemiology and prevention of hepatitis B. Semin. Liver Dis. 23 1 (2003) 39-46
2. Anneke K.R., Robert K.H., and Zhi H. Agents in clinical development for the treatment of chronic hepatitis B. Expert Opin. Inv. Drug 12 8 (2003) 1281-1295
3. Averhoff F., Mahoney F., Coleman P., Schatz G., Hurwitz E., and Margolis H. Immunogenicity of hepatitis B vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am. J. Prev. Med. 15 1 (1998) 1-8
4. Shepard C.W., Simard E.P., Finelli L., Fiore A.E., and Bell B.P. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev. 28 (2006) 112-125
5. Zoulim F., Buti M., and Lok A.S. Antiviral-resistant hepatitis B virus: can we prevent this monster from growing?. J. Viral Hepat. 14 Suppl. 1 (2007) 29-36
6. Marcellin P., Asselah T., and Boyer N. Treatment of chronic hepatitis B. J. Viral Hepat. 12 4 (2005) 333-345
7. Liu J., Li Y.H., Xue C.F., Ding J., Gong W.D., Zhao Y., and Huang Y.X. Targeted ribonuclease can inhibit HBV replication. Zhonghua Gan Zang Bing Za Zhi 12 3 (2004) 179
8. Natsoulis G., and Boeke J.D. New antiviral strategy using capsid-nuclease fusionproteins. Nature 352 6336 (1991) 632-635
9. Schumann G., Hermankova M., Cannon K., Mankowski J.L., and Boeke J.D. Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection in vivo. J. Virol. 75 15 (2001) 7030-7041
10. Qin C.F., Qin E., Yu M., Chen S.P., Jiang T., Deng Y.Q., Duan H.Y., and Zhao H. Therapeutic effects of dengue 2 virus capsid protein and staphylococcal nuclease fusion protein on dengue-infected cell cultures. Arch. Virol. 150 4 (2005) 659-669
11. Beterams G., and Nassal M. Significant interference with hepatitis B virus replication by a core-nuclease fusion protein. J. Biol. Chem. 276 12 (2001) 8875-8883
12. Ding J., Liu J., Xue C.F., Gong W.D., Li Y.H., and Zhao Y. Anti-HBV effect of TAT- HBV targeted ribonuclease. World J. Gastroenterol. 9 7 (2003) 1525-1528
13. Gong W.D., Liu J., Ding J., et al. Inhibition of HBV targeted ribonuclease enhanced by introduction of linker. World J. Gastroenterol. 9 7 (2003) 1504-1507
14. Li Y.h., Liu J., and Xue C.f. Construction of HBV targeted ribonuclease and its expression in 2.2.15 cell line. Chin. J. Cell. Mol. Immunol. 18 3 (2002) 217-220
15. Nyberg-Hoffman C., Shabram P., Li W., Giroux D., and Aguilar-Cordova E. Sensitivity and reproducibility in adenoviral infectious titer determination. Nat. Med. 3 7 (1997) 808-811
16. Takehara T., Suzuki T., Ohkawa K., Hosui A., Jinushi M., Miyagi T., Tatsumi T., Kanazawa Y., and Hayashi N. Viral covalently closed circular DNA in a non-transgenic mouse model for chronic hepatitis B virus replication. J. Hepatol. 44 2 (2006) 267-274
17. Ng P., Parks R.J., Cummings D.T., Evelegh C.M., Sankar U., and Graham F.L. High-efficiency Cre/loxP-based system for construction of adenoviral vectors. Hum. Gene Ther. 10 16 (1999) 2667-2672
18. Binley K., Askham Z., Martin L., et al. Hypoxia-mediated tumour targeting. Gene Ther. 10 7 (2003) 540-549
19. Peng Z.H. Current status of Gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Hum. Gene Ther. 16 9 (2005) 1016-1027
20. Jalkanen J., Leppanen P., Narvanen O., et al. Adenovirus-mediated gene transfer of a secreted decoy human macrophage scavenger receptor (SR-AI) in LDL receptor knock-out mice. Atherosclerosis 169 1 (2003) 95-103
21. George J.S. Gene therapy progress and prospects: adenoviral vectors. Gene Ther. 10 (2003) 1135-1141